Product Pathways - Cell Cycle / Checkpoint
Nocodazole #2190
- Molecular Formula:
- C14H11N3O3S
- Molecular Weight:
- 301.3 g/mol
- Purity:
- >97%
Directions for Use
Nocodazole is supplied as a lyophilized powder. For a 1 mg/ml stock, reconstitute the 10 mg in 10 ml DMSO. Working concentrations and length of treatments vary depending on the desired effect, but it is typically used at 0.1-1 µg/ml for 12-48 hr. Soluble in DMSO.
Western Blotting
Western blot analysis of extracts from HeLa cells untreated (-) or treated with Nocodazole (0.1 μg/ml, 18 hr; +) or λ phosphatase (+), using Phospho-Histone H3 (Ser10) (D2C8) XP® Rabbit mAb #3377 (upper) or Histone H3 Antibody #9715 (lower).
Western Blotting
Western blot analysis of extracts from HeLa cells, untreated (-) or treated with Nocodazole (0.1 μg/ml, 18 hr; +), using Phospho-NPM (Ser4) (D19C1) XP® Rabbit mAb #3520 (upper) or NPM Antibody #3542 (lower).
Structure
Chemical structure of nocodazole.
Background
Nocodazole is an anti-neoplastic agent that reversibly interferes with the polymerization of microtubules (1). Widely-used as a cell cycle synchronizing agent in cell biology labs to induce mitotic arrest, investigators have demonstrated that high concentrations of nocodazole induce microtubule depolymerization, whereas low concentrations alter spindle microtubule dynamics, but microtubules do not depolymerize (2-4). Recent research studies have demonstrated nocodazole to be a common inhibitor of various cancer-related kinases, including: ABL, c-KIT, BRAF, MEK1, MEK2, and MET (5).
- De Brabander, M.J. et al. (1976) Cancer Res 36, 905-16.
- Vasquez, R.J. et al. (1997) Mol Biol Cell 8, 973-85.
- Jordan, M.A. et al. (1992) J Cell Sci 102 ( Pt 3), 401-16.
- Blajeski, A.L. et al. (2002) J Clin Invest 110, 91-9.
- Park, H. et al. (2012) ChemMedChem 7, 53-6.
Application References
Have you published research involving the use of our products? If so we'd love to hear about it. Please let us know!
For Research Use Only. Not For Use In Diagnostic Procedures.
